Get access

Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects

Authors

  • Si Tianmei,

    Corresponding author
    1. Department of Clinical Psychopharmacology, Peking University Institute of Mental Health, Huayuanbeilu 51, Haidian District, Beijing, China
    • Department of Clinical Psychopharmacology, Peking University Institute of Mental Health, Huayuanbeilu 51, Haidian District, Beijing, 100191, China.
    Search for more papers by this author
  • Shu Liang,

    1. Department of Clinical Psychopharmacology, Peking University Institute of Mental Health, Huayuanbeilu 51, Haidian District, Beijing, China
    Search for more papers by this author
  • Liu Yi,

    1. Department of Clinical Psychopharmacology, Peking University Institute of Mental Health, Huayuanbeilu 51, Haidian District, Beijing, China
    Search for more papers by this author
  • Su Yun'Ai,

    1. Department of Clinical Psychopharmacology, Peking University Institute of Mental Health, Huayuanbeilu 51, Haidian District, Beijing, China
    Search for more papers by this author
  • Guo Chunmei,

    1. Department of Clinical Psychopharmacology, Peking University Institute of Mental Health, Huayuanbeilu 51, Haidian District, Beijing, China
    Search for more papers by this author
  • Zhang Hongyan

    1. Department of Clinical Psychopharmacology, Peking University Institute of Mental Health, Huayuanbeilu 51, Haidian District, Beijing, China
    Search for more papers by this author

Abstract

Objective

Paliperidone is the active metabolite of risperidone. This single-center, double-blind, randomized, single-dose study characterized the pharmacokinetics of 3 mg and 9 mg of paliperidone ER OROS® in healthy Chinese subjects.

Methods

24 subjects (13 male, 11 female), aged 19–35 years, with a BMI of 19.0–24.6 kg/m2 participated. Blood samples were collected immediately before and over 96 h following single oral doses of 3 mg and 9 mg paliperidone. Plasma paliperidone concentrations were determined, and pharmacokinetic parameters were analyzed.

Results

Paliperidone's disposition after oral administration was characterized by a one-compartment pharmacokinetic model. Paliperidone was well absorbed (median tmax: 24 h after a 3-mg dose, and 26 h after a 9-mg dose). Apparent clearance and apparent volume of distribution were not significantly different between the two doses. Cmax, AUC0-t, and AUC0-∞ were dose-dependent. Pharmacokinetics was linear with respect to time; Geometric mean t1/2 was 22.8 h and 21.4 h in 3-mg and 9-mg groups, respectively. No clinically significant safety issues were identified.

Conclusions

The pharmacokinetic results obtained in Chinese subjects were similar to those obtained in Japanese and Caucasian subjects. Copyright © 2010 John Wiley & Sons, Ltd.

Ancillary